Skip to main content
Experience

Representing Sandoz in a putative class action relating to the hyper-tension drug Valsartan

Fasken
Reading Time 1 minute read
Share
  • LinkedIn

Overview

Client

Sandoz

The petitioner seeks authorization to institute a class action on behalf of all persons in Quebec who were prescribed and who consumed the drug Valsartan. The claim alleges that the drug had adverse side effects about which the respondents failed to warn. The certification of this matter has not yet been heard.

Fasken acted for Sandoz Canada Inc., Pro Doc Limitée, Sanis Health Inc. and Sivem Pharmaceuticals ULC in this putative class action launched in Quebec with a team comprised of Peter Pliszka and Noah Boudreau.

Team

  • Noah Boudreau, Partner | Litigation and Dispute Resolution, Montréal, QC, +1 514 394 4521, [email protected]
  • Peter J. Pliszka, Partner | CHAIR, LIFE SCIENCES LITIGATION | CHAIR, PRODUCT LIABILITY & INSURANCE GROUP, Toronto, ON, +1 416 868 3336, [email protected]
Noah Boudreau Avocat/Associate Montréal Noah Boudreau Partner | Litigation and Dispute Resolution Montréal, QC +1 514 394 4521
Peter J Pliszka Toronto Lawyer Peter J. Pliszka Partner | CHAIR, LIFE SCIENCES LITIGATION | CHAIR, PRODUCT LIABILITY & INSURANCE GROUP Toronto, ON +1 416 868 3336